Clinical trials located in

Almada

Almada city is located in Portugal. Currently, 20 clinical trials are being conducted in this city.

Almada, located on the southern bank of the Tagus River in Portugal, is known for its picturesque views of Lisbon and the iconic 25 de Abril Bridge. The city boasts the Cristo Rei statue, a monumental Christ figure mirroring Rio de Janeiro’s Christ the Redeemer, which stands as a symbol of peace. Almada’s coastline, particularly the Costa da Caparica area, offers extensive sandy beaches that stretch over 13 kilometers, making it a favored spot for surfers and beachgoers. The city’s blend of historical sites, modern architecture, and natural beauty creates a unique cultural landscape.

  • CT-EU-00116184

    A study comparing upadacitinib versus adalimumab in the treatment of rheumatoid arthritis

    This clinical trial is studying a new medication called upadacitinib for treating moderate to severe rheumatoid arthritis. Rheumatoid arthritis is a chronic condition that causes pain, stiffness, swelling, and loss of joint function. The study will compare upadacitinib, which is taken as an oral tablet once daily, to adalimumab (brand name Humira), which is an injection given under the skin every other week.

    The main goal is to see how effective upadacitinib is at reducing disease activity compared to adalimumab. The study will measure the percentage of participants who achieve a certain level of low disease activity based on a score called the DAS28-CRP, which looks at tender and swollen joints, overall disease activity, and inflammation levels.

    This is a double-blind study, meaning neither the participants nor the study doctors will know which treatment each participant is receiving. Participants will attend regular visits at a hospital or clinic for medical assessments, checking for side effects, and completing questionnaires. There may be a higher treatment burden compared to standard care. The study is designed to assess the safety and effectiveness of upadacitinib compared to adalimumab in treating moderate to severe rheumatoid arthritis.

    • Adalimumab
    • Upadacitinib
  • Assessing imatinib inhalation therapy for pulmonary arterial hypertension

    This clinical study aims to evaluate the safety and efficacy of an inhaled treatment called imatinib (AV-101) for patients with Pulmonary Arterial Hypertension (PAH). The trial is divided into two parts: Phase 2b and Phase 3. In Phase 2b, researchers will test three doses of AV-101 to identify the optimal dose for Phase 3. They will check this by measuring the resistance of the lung vessels — less resistance means the medicine is working. In the following Phase 3, the primary outcome will be the change in the 6-minute walk distance after 24 weeks of treatment compared to a placebo. Participants must be between 18 and 75 years old, have a diagnosis of PAH, and meet specific criteria regarding their disease severity and concomitant therapy.

    • Imatinib/AV-101
  • Testing inhaled imatinib for pulmonary arterial hypertension

    This study is about a new medicine called imatinib (AV-101) which you breathe in as a dry powder. It’s for people who have a health problem called Pulmonary Arterial Hypertension (PAH) – when blood pressure is too high in the arteries that go from the heart to the lungs. The imatinib study will go through two stages. In the first stage, the researchers will try three different amounts of the medicine to find the best one. It will be based on how much it can reduce the resistance in the blood flow in the lungs. In the second stage, they it will be seen how far patients can walk in 6 minutes after taking the medicine for 24 weeks. The study also uses scoring systems to measure how much risk or symptoms a patient has. A higher score means more risk or symptoms.

    • imatinib/ AV-101
  • Evaluating dostarlimab for treating stage III colon cancer

    This research is focused on the investigation of the effect of dostarlimab on patients with severe, untreated colon cancer (T4N0 or Stage III dMMR/MSI-H). The primary objective is to assess whether dostarlimab yields superior outcomes for the patients in comparison to standard treatments. Patient monitoring will be based on tumor response and the potential impact on their quality of life resulting from the drug or disease progression.

    • CAPEOX
    • Dostarlimab
    • FOLFOX
  • Testing gefurilimab treatment in patients with myasthenia gravis

    This study is looking at a potential treatment for a disease called generalized myasthenia gravis (gMG) in adults. It’s called gefurulimab (ALXN1720). For our study, researchers will divide participants into two groups, each of which will be treated differently. One group will receive the new drug. Importantly, the researchers conducting the study will not know who received which treatment. This ensures the fairness and accuracy of the results. Participants’ health will be closely monitored to ensure that ALXN1720 is safe. The main goal is to check whether new mediations are effective. It will be measured by checking whether patients’ condition has improved compared to when the study started. This will take approximately 26 weeks.

    • gefurulimab/ALXN1720
  • Sotatercept treatment study for new Pulmonary Hypertension patients

    This study is an important test where doctors are looking at how a drug called Sotatercept can help people struggling with Pulmonary Arterial Hypertension (or PAH for short). The goal is to see whether this drug can delay or prevent the condition from getting worse. PAH makes it really hard for patients to breathe because it affects lungs and heart. The testing process is being done in a fair and careful way. Half of the patients will get the drug, and the others will get a ‘placebo’ which doesnt contain any medicine. The doctors will look at the effect on patients over time. The study is looking specifically at patients who were recently diagnosed with PAH and are at risk for the disease to get worse.

    • Sotatercept
  • Comparing the effectiveness of two treatments for severe nasal polyps and asthma

    This study is looking at two medications, called Dupilumab and Omalizumab, to see how well they work in people who have severe nose and sinus problems alongside asthma. The main goal is to see if Dupilumab is better at shrinking nasal polyps (small growths in the nose) and improving the sense of smell. Other goals include seeing if Dupilumab can improve symptoms, lung function, and overall health-related quality of life better than Omalizumab. The study also aims to understand how these drugs affect the severity of the disease and asthma control, and their safety. To assess all these, doctors will use various tests, like measuring the size of nasal polyps, testing the ability to smell, and how well one’s lungs are working. Participants in the study will be involved for 38 weeks.

    • Dupilumab
    • Omalizumab
  • Pralsetinib vs regular care in treating advanced lung cancer

    This study is looking at how effective a medication called Pralsetinib is in treating a type of lung cancer called RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer. This cancer type is difficult to treat and usually spreads to other parts of the body. The medicine will be compared to the usual treatments given for this type of cancer. Doctors want to see if Pralsetinib can slow down or stop the cancer progression and how long that lasts. Any side effects experienced by patients will be carefully monitored to understand the medication’s safety.

    • Pralsetinib
    • Gemcitabine
    • Pemetrexed
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
    • nab-Paclitaxel
    • Paclitaxel
  • Testing mavacamten for heart muscle disease

    This study aims to assess a drug called Mavacamten for a heart condition called Non-Obstructive Hypertrophic Cardiomyopathy. Patients will be randomly given either the actual drug or a placebo without anyone knowing which one they’ve received. The study will measure how safe and effective the drug is for patients with symptoms of this heart condition. The success of the drug will be determined by preventing heart-related issues such as heart attacks, strokes, heart failures, irregular heartbeats, and the need for a heart-rhythm controlling device.

    • Mavacamten
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Study of secukinumab treatment for Giant Cell Arteritis

    This study is testing a drug called Secukinumab to see if it is safe and effective in people with a disease known as giant cell arteritis (GCA). GCA affects blood vessels in the body, causing inflammation. In this study, patients will receive Secukinumab or placebo (a treatment without active medicine) along with a medicine called glucocorticoids, the dose of which will be gradually reduced. The test will test whether a 26-week treatment course is more effective than the current 52-week treatment course. The research team will monitor whether the inflammation subsides and does not return throughout the year. The team will also check how long it will take until the disease symptoms return, how many glucocorticosteroids the patient will need within a year and how his quality of life has improved.

    • Secukinumab
  • Comparing atogepant and topiramate for migraine prevention

    In this study, a comparison is being made between two different medicines aimed at preventing migraines in adults. Migraines manifest as severe headaches on one side of the head, accompanied by symptoms such as nausea, throbbing pain, or sensitivity to light and sound. The two medicines under comparison are named atogepant and topiramate. Atogepant is currently employed for migraine prevention in individuals experiencing migraines from 0 to 14 days per month, and the study seeks to evaluate its potential broader application. Topiramate is already widely utilized for migraine prevention. Participants in this study will be divided into two groups: one group will be administered atogepant, while the other will receive topiramate for a duration of 24 weeks. Following this period, those eligible to continue will all receive atogepant for an additional 52 weeks. The study will assess their progress and monitor any potential side effects.

    • Topiramate
    • Atogepant
  • Exploring new vs usual treatment for bladder cancer

    This clinical trial is testing a new combination of two drugs, Gemcitabine Hydrochloride (TAR-200) and Cetrelimab, with people who have a certain type of bladder cancer called Muscle invasive bladder cancer (MIBC). The study aims to see if these drugs work better than the usual treatment of chemotherapy and radiation therapy. The goal is to see which one keeps the bladder cancer-free for longer. Doctors also follow up with patients to record any side effects from the treatments.

    • Gemcitabine Hydrochloride/TAR-200
    • Cetrelimab
    • Gemcitabine
    • Cisplatin
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    • Olpasiran
  • Exploring Fipaxalparant as a new treatment method for Diffuse Cutaneous Systemic Sclerosis

    This extensive study, conducted across multiple hospitals, aims to assess the effectiveness and safety of a Fipaxalparant (HZN-825), in individuals with a skin condition known as Diffuse Cutaneous Systemic Sclerosis. The study employs a double-blind design, where some participants receive the actual drug, and others receive a placebo (a drug with no active substance), with neither the doctors nor the patients being aware of which treatment they are receiving. The trial is scheduled to run for approximately one year, with regular check-ups every six weeks. If participants successfully complete the year-long trial, they may be invited to continue using the drug for an additional year in a follow-up study. For safety reasons, a check-up will also be conducted four weeks after participants stop taking the drug.

    • Fipaxalparant/HZN-825
  • Testing the efficacy of teclistamab vs other drugs for relapsed or refractory multiple myeloma treatment

    The study is evaluating a treatment for a blood cancer known as multiple myeloma. Two different treatments are being compared to assess their effectiveness in both slowing down the disease and minimizing side effects. The first treatment involves a single medicine called teclistamab, while the second offers a choice between two combinations of multiple medicines (either PVd – pomalidomide, bortezomib, dexamethasone or Kd – carfilzomib, dexamethasone). Both treatments have been previously administered to individuals with similar conditions. Individuals who have undergone prior treatment, including the use of an anti-CD38 monoclonal antibody and lenalidomide, but experienced a recurrence or lack of resolution of the disease, are eligible to participate in this study. The objective is to determine the duration it takes for the disease to progress under different treatments. Additionally, the study will monitor changes in health and potential medication-related issues through regular check-ups.

    • Carfilzomib
    • Pomalidomide
    • Teclistamab
    • Dexamethasone
    • Bortezomib
  • Thrombolysis therapy in treating acute Pulmonary Embolism

    This study aims to evaluate a reduced dose of thrombolytic treatment for patients with intermediate-high-risk acute pulmonary embolism. It compares the new treatment approach with a placebo to assess effectiveness and safety. The study’s focus is on reducing the risk of major and intracranial bleeding associated with full-dose thrombolytic treatment. Participants will receive either the experimental treatment or a placebo, alongside standard anticoagulation therapy. The primary goal is to determine the efficacy and safety of the reduced dosage at day 30, with long-term follow-up assessments planned. This research is crucial for improving treatment options for patients with this serious lung condition.

    • Alteplase
  • Study on new immunotherapy combinations for throat and neck cancer treatment

    This study evaluated advanced immunotherapeutic treatments for PD-L1-positive head and neck squamous cell carcinoma. The study involves comparing innovative combinations of immunotherapy with dostarlimab monotherapy to select the most effective treatment method. It focuses on patients with recurrent or metastatic cancer and aims to improve survival rates and response to treatment.

    • Belrestotug
    • Dostarlimab
    • GSK6097608- new potential medication for solid tumors
  • Long-term safety & effectiveness of rocatinlimab for atopic dermatitis

    This trial is all about studying a medicine called rocatinlimab for grown-ups and teens with a serious skin disease named atopic dermatitis (AD). The main goal is to see if rocatinlimab is safe and can help over a long period. The research will also check how well people tolerate the medication. The focus is on those who previously benefitted from the medicine, showing an improvement on a scoring system that measures itching levels. This trial falls in the third phase, making it crucial towards verifying the effectiveness and monitoring any adverse effects of the drug.

    • Rocatinlimab

See more clinical trials in other cities in Portugal:

.